Atossa Therapeutics (Atossa Therapeutics) Equity-to-Asset : 0.95 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Atossa Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $91.02 Mil. Atossa Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $96.25 Mil.

The historical rank and industry rank for Atossa Therapeutics's Equity-to-Asset or its related term are showing as below:

ATOS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6 Med: 0.83 Max: 0.98
Current: 0.95

During the past 13 years, the highest Equity to Asset Ratio of Atossa Therapeutics was 0.98. The lowest was 0.60. And the median was 0.83.

ATOS's Equity-to-Asset is ranked better than
95.08% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs ATOS: 0.95

Atossa Therapeutics Equity-to-Asset Historical Data

The historical data trend for Atossa Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Equity-to-Asset Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.91

0.63

0.98

0.96

0.95

Atossa Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.96	0.98	0.97	0.97	0.95

Competitive Comparison of Atossa Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Atossa Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Equity-to-Asset falls into.

Atossa Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Atossa Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	91.016	/	96.252
	=

Atossa Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	91.016	/	96.252
	=

Atossa Therapeutics (NAS:ATOS) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Atossa Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (Atossa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Executives

Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees	officer: SVP, Finance and Accounting	C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse	officer: CFO & General Counsel	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
H. Lawrence Remmel	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Shu-chih Chen	director, 10 percent owner, officer: Chief Scientific Officer	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay	director, 10 percent owner, officer: CEO	22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans	officer: Chief Operating Officer	ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer	officer: See Remarks	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro	officer: SVP, Sales and Marketing	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro	officer: Sr. Vice President, Operations	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen	officer: Sr. VP of Glob. Reg. Affairs	1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross	director	C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart	director	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112